Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL7P61 (ribosomal protein L7 pseudogene 61) is a processed pseudogene related to the RPL7 gene, which encodes the ribosomal protein L7, a component of the 60S subunit of the ribosome. As a processed pseudogene, RPL7P61 does not encode a functional protein and is not known to participate in any biological pathway, disease process, or serve as a drug target[6][7][2]. Processed pseudogenes such as RPL7P61 are gene sequences that arise from retrotransposition events; they resemble their parent gene but generally do not have coding potential or biological function[2]. Therefore, RPL7P61 is not considered a therapeutic target, and no drugs, biomarkers, or safety concerns are associated with it. There are no known biological activities, drug interactions, or disease associations for RPL7P61, and it should not be classified as a valid therapeutic target[6][7]. Its sole relevance is as a genomic sequence related to the RPL7 parent gene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7 pseudogene 61 (RPL7P61).